Opendata, web and dolomites

BioTrace SIGNED

World's First Real-Time Monitoring System for Ablation Procedures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BioTrace project word cloud

Explore the words cloud of the BioTrace project. It provides you a very rough idea of what is the project "BioTrace" about.

8m    300    thermal    arrhythmias    2017    global    monitor    works    minimally    algorithms    margin    hospital    alerted    dying    surgery    latest    industry    alternative    changer    proven    cells    damage    heat    million    interventional    device    keeping    reducing    knowing    viability    standalone    40    cancer    outcome    university    healthcare    post    commercial    roi    pain    opportunity    procedure    uth    38    ai    rates    sales    costly    treat    foresee    tumours    treatment    24    time    technique    resection    feasibility    28    area    progression    35    market    ta    solution    track    outside    remove    ablation    smaller    revenues    undertreatment    patients    biological    cardiac    physicians    continue    fifth    electrophysiology    gold    invasive    considering    clinical    unfit    limited    neurotomy    2023    oncology    hours    recurrence    financial    complete    unpredictability    biotrace    tokyo    intervention    surgical    predicts    game    liver    treating    standard    frequently    estimate    54    lesion    risky    tissue   

Project "BioTrace" data sheet

The following table provides information about the project.

Coordinator
TECHSOMED MEDICAL TECHNOLOGIES LTD 

Organization address
address: MEIR WEISGAL 2 ST., SCIENCE PARK
city: REHOVOT
postcode: 7632605
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHSOMED MEDICAL TECHNOLOGIES LTD IL (REHOVOT) coordinator 50˙000.00

Map

 Project objective

Cancer treatment resection or surgery is currently the gold standard to remove tumours, but it is risky for patients and a costly process (average cost of €28.000 per surgery). Ablation is a minimally invasive technique and the best alternative to surgery (€1,300). However, its use is still limited to treat patients with smaller tumours or patients unfit for surgery, due to its high unpredictability, as there is currently no way of knowing the extent of the lesion during and after the intervention (cells continue dying for up to 24 hours after the intervention due to thermal effects). Thus, undertreatment or over treatment frequently occur, the latest leading to up to 40% recurrence. Our solution, BioTrace, is the only device able to monitor in real-time the extent of the lesion during the ablation procedure and predicts its outcome 24 hours post-treatment. It works by keeping track of the tissue's biological response to the heat using AI-based algorithms. With BioTrace physicians are alerted when damage is observed outside the surgical margin, which enables them to determine its progression 24 hours after the procedure (as proven in a clinical study conducted with 54 standard TA procedures in University of Tokyo Hospital (UTH)). BioTrace will be a game-changer in the ablation technology industry by improving success rates and reducing costs for the healthcare system. Its market opportunity is large since it can be applied not only in the interventional oncology area, but in other areas, such as electrophysiology (for treating cardiac arrhythmias) and neurotomy (for pain management). We foresee that we will need €3 million to complete phase 2 and reach the liver market as a standalone system. Considering a growth of the global ablation market of 35% (2017-2023), in the fifth year of sales we estimate to reach revenues of 10.8M and a ROI of 0.38. During the feasibility study we will further assess the technical, commercial and financial viability of our project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOTRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOTRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More